New opioid fee funds disposal sites; cancer patients exempted, others pay more

What it does

This bill amends the Comprehensive Addiction and Recovery Act to authorize the Attorney General to award grants to establish or maintain prescription medication disposal sites, funded by a new 1-cent-per-100-milligrams fee on opioid sales. Cancer patients, hospice patients, and their families are exempted from paying the fee through a discount mechanism administered by HHS.

Why we flagged it

The bill's operative mechanism is a targeted excise tax on opioid sales to fund a specific public health infrastructure (medication disposal sites). It is not a broad tax or subsidy, but a narrow revenue instrument tied to a named purpose.

What the text implies

• The 1-cent fee is per 100mg of active opioid, meaning higher-dose formulations incur proportionally higher fees; manufacturers may pass costs to consumers, potentially increasing out-of-pocket costs for non-exempted patients.
• The bill does not specify how HHS will operationalize the discount mechanism for eligible patients; implementation complexity and administrative burden on pharmacies/prescribers could delay or limit the exemption's effectiveness.
• Disposal sites funded by this mechanism may concentrate in urban/well-resourced areas; rural and underserved communities may see uneven access to disposal infrastructure despite the national fee.
• The fee applies to all active opioids including prescription painkillers; patients on long-term opioid therapy for non-cancer chronic pain are not exempted and will bear the full fee cost.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a public health benefit (expanded medication disposal infrastructure, reducing environmental contamination and accidental poisoning) but shifts the cost to opioid consumers via a new fee, which may increase medication prices for patients not exempted. Vulnerable populations (cancer, hospice) are protected, but others pay more.

Who stands to gain

• Entities awarded disposal-site grants (law enforcement, nonprofits, healthcare systems)
• Pharmacy and healthcare infrastructure providers managing disposal sites

Named in the bill

Attorney General, Drug Enforcement Administration (DEA), Secretary of Health and Human Services (HHS), Director of Office of National Drug Control Policy (ONDCP), Opioid manufacturers, producers, importers, State, local, tribal law enforcement agencies, Reverse distributors of prescription medications, Comprehensive Addiction and Recovery Act of 2016, Controlled Substances Act

Where it stands

1 cosponsor: 1 Republicans.

• Oct 1, 2026 — Introduced · Congress.gov: “Introduced in House”
• Oct 1, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.